Nausea · people with schizophrenia with antipsychotic‐induced weight gain
Metformin showed no clear difference in reports of nausea compared with placebo or no treatment (low certainty).
1 finding from 1 review
Diabetes · Adults with mental disorders in low‐ and middle‐income countries
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Drop‐out Objective · Adults with mental disorders in low‐ and middle‐income countries
Metformin showed no clear difference in drop‐outs (12 to 14 weeks) compared with placebo (moderate certainty).
1 finding from 1 review
Fasting blood glucose (mg/dL) · Adults with mental disorders in low‐ and middle‐income countries
2 findings from 1 review
Body‐mass index (BMI) · Adults with mental disorders in low‐ and middle‐income countries
1 finding from 1 review
Dropout · opiate‐dependent pregnant women
Methadone showed no clear difference in dropout rate compared with buprenorphine (moderate certainty).
1 finding from 1 review
Birthweight (g) · opiate‐dependent pregnant women
1 finding from 1 review
APGAR score (APGAR score ) · opiate‐dependent pregnant women
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events for the mother · opiate‐dependent pregnant women
1 finding from 1 review
Serious adverse events for the child · opiate‐dependent pregnant women
1 finding from 1 review
Use of Primary Substance · opiate‐dependent pregnant women
Methadone showed no clear difference in use of primary substance compared with buprenorphine (low certainty).
1 finding from 1 review
Birthweight (g) · opiate‐dependent pregnant women
1 finding from 1 review
APGAR scoreScale from: 0 to 10 · opiate‐dependent pregnant women
1 finding from 1 review
Number treated for NAS · opiate‐dependent pregnant women
Methadone showed no clear difference in number treated for NAS compared with buprenorphine (low certainty).
1 finding from 1 review
Proportion of mothers with serious adverse events ( · opiate‐dependent pregnant women
Methadone showed no clear difference in serious adverse events for the mother compared with buprenorphine (low certainty).
1 finding from 1 review
Serious adverse events for the child · opiate‐dependent pregnant women
Methadone showed no clear difference in serious adverse events for the child compared with buprenorphine (low certainty).
1 finding from 1 review
Unacceptability of treatment (dropouts/exclusions during the trial) · opiate‐dependent pregnant women
1 finding from 1 review
Use of substance · opiate‐dependent pregnant women
Methadone showed no clear difference in use of substance compared with oral slow‐release morphine (low certainty).
1 finding from 1 review
Treatment responsea · children and young people with JIA
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Sustained clinically inactive diseasec · children and young people with JIA
Oral methotrexate plus intra‐articular glucocorticoid showed no clear difference in sustained clinically inactive diseaseb(12 months) compared with intra‐articular glucocorticoid alone (low certainty).
1 finding from 1 review